NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Nasal Drops for Glioblastoma Treatment and BioMedWire Announcement
TL;DR
CNS Pharmaceuticals Inc. is developing nasal drop therapeutics that could give them a competitive edge in treating glioblastoma by directly targeting brain cancer cells.
Washington University research shows nasal drops travel through nasal nerves to reach the central nervous system, delivering therapeutics directly to glioblastoma cells.
This nasal drop technology offers hope for better glioblastoma treatments, potentially improving survival rates and quality of life for brain cancer patients.
Nasal drops can bypass the blood-brain barrier, using nasal nerves as a direct pathway to fight deadly brain cancer cells.
Found this article helpful?
Share it with your network and spread the knowledge!
This announcement covers new research on nasal drops that can fight glioblastoma (a deadly brain cancer) by traveling through nerves in the nose to reach the central nervous system, along with information about related therapeutics development and BioMedWire's communications platform.
The nasal drops travel through nerves found in the nose and reach different parts of the central nervous system in order to fight glioblastoma cells there.
The research was conducted at Washington University, as indicated by the study link provided in the content.
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is mentioned as developing therapeutics against glioblastoma.
The latest news and updates relating to CNS Pharmaceuticals Inc. are available in the company's newsroom at https://ibn.fm/CNSP.
BioMedWire is a specialized communications platform focusing on Biotechnology, Biomedical Sciences and Life Sciences sectors that provides wire solutions, article syndication, press release enhancement, social media distribution, and corporate communications solutions through the Investor Brand Network.
To receive SMS alerts from BioMedWire, text "Biotech" to 888-902-4192 (U.S. Mobile Phones Only).
For more information, visit https://www.BioMedWire.com, and for terms of use and disclaimers, visit https://www.BioMedWire.com/Disclaimer.
Readers can contact BioMedWire at Editor@BioMedWire.com or call 415.949.5050 Office.
Curated from InvestorBrandNetwork (IBN)
